Bank of America Corp DE Buys Shares of 78,744 Septerna, Inc. (NASDAQ:SEPN)

Bank of America Corp DE bought a new stake in shares of Septerna, Inc. (NASDAQ:SEPN - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 78,744 shares of the company's stock, valued at approximately $1,803,000. Bank of America Corp DE owned about 0.18% of Septerna at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. JPMorgan Chase & Co. bought a new position in Septerna in the 4th quarter worth approximately $871,000. Jane Street Group LLC bought a new position in Septerna in the 4th quarter worth approximately $600,000. MetLife Investment Management LLC bought a new position in Septerna in the 4th quarter worth approximately $265,000. Barclays PLC bought a new position in Septerna in the 4th quarter worth approximately $659,000. Finally, TRV GP VI LLC bought a new position in Septerna in the 4th quarter worth approximately $72,191,000.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on SEPN. Cantor Fitzgerald increased their price objective on Septerna from $20.00 to $25.00 and gave the stock an "overweight" rating in a report on Friday, May 16th. Wells Fargo & Company upped their target price on Septerna from $11.00 to $18.00 and gave the stock an "equal weight" rating in a research report on Friday, May 16th.

Septerna Stock Performance

SEPN traded down $0.31 during trading on Friday, reaching $10.21. The stock had a trading volume of 840,163 shares, compared to its average volume of 709,808. Septerna, Inc. has a 1-year low of $4.17 and a 1-year high of $28.99. The stock has a 50 day moving average of $7.49 and a two-hundred day moving average of $12.83.

Septerna (NASDAQ:SEPN - Get Free Report) last released its earnings results on Thursday, May 15th. The company reported ($0.49) earnings per share for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.11). The business had revenue of $0.22 million during the quarter. Research analysts predict that Septerna, Inc. will post -7.11 EPS for the current fiscal year.

Septerna Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.